Gagnon Robert E.

Gagnon Robert E. is listed in filings as Chief Financial Officer at Opus Genetics, Inc.. This profile follows SEC Form 4 activity through Apr 27, 2026, including sale activity. Recent filings connect the profile to Opus Genetics, Inc. (IRD), Verastem, Inc. (VSTM), Harvard Bioscience, Inc. (HBIO), and Bone Biologics Corporation (BBLGW). The current snapshot covers public activity from Jun 20, 2024 to Apr 27, 2026. Reported amounts are shown as $40.7K to $2.8K. The page organizes purchases, sales, issuer links, reported share activity, and filing evidence for review as public disclosure data.